2020 Update on the Treatment of Pituitary Tumors: Emerging Therapies

After completion of this didactic and case-based educational activity, participants will be up to date on the latest developments in ongoing basic and translational science as well as the clinical management of patients with pituitary conditions. Participants will be able to:

• Review available and emerging medical therapies for Cushing’s and acromegaly
  
• Discuss new mechanisms and therapies for aggressive and malignant tumors
  
• Understand decision making involved in surgical intervention for pituitary tumors
  
• Get an overview on potential surgical complications
  
• Describe the role of radiation therapy for pituitary tumors
  
• Discuss mechanisms of immunotherapy-related pituitary dysfunction
  
• Assess advances in neuroimaging and tumor markers that may predict tumor behavior and clinical outcomes

Overall this course aims to improve patient care and outcomes through evidence-based discussion of clinical practice guidelines and emerging therapies. Our goal is to assess and update current practices to promote earlier diagnosis and treatment of pituitary diseases. The multidisciplinary nature of the course will allow for dissemination of knowledge across the variety of practitioners caring for pituitary patients, and for the patients themselves.

Provider/Clinical Track

Request for Case Submissions - There will be a tumor board during the provider/clinical breakout session where attendees and faculty will review cases. Attendees will have an opportunity to submit a case for discussion during the course at registration. In order to prepare your submission, we ask that you provide a BRIEF summary of your case and include key lab results. Please ensure that all identifiable PHI has been removed. Cases should have an educational purpose. The course faculty will not be able to provide a detailed/complex consult review during the course and they will try to get through as many cases as possible.

Patient Track

We also invite patients with pituitary disease and their caregivers to attend this educational activity and participate in our interactive afternoon breakout sessions. Pituitary patients will be able to review treatment options, learn about ongoing clinical trials, and discuss their comprehensive care with providers and other patients. The educational objective of this patient session is to provide a forum for pituitary patients to discuss treatment options and new therapies with providers and other patients. Please note AMA PRA Category 1 Credits™ will not be offered for the patient breakout session.  

MSK is pleased to invite patients and caregivers to attend this course on a complimentary basis. If you are a patient or caregiver interested in attending, please email [email protected] to register (registration is required in order to attend).

Target Audience

This course is intended for endocrinologists, neurosurgeons, otolaryngologists, radiation oncologists, neurologists, ophthalmologists, neuro-oncologists, family medicine and internal medicine physicians, physicians in training and other allied health professionals who treat and manage patients with pituitary diseases. We also invite patients with pituitary disease and their caregivers to attend this educational activity and participate in our interactive afternoon breakout sessions.

1. Review the efficacy and side effect profiles of treatment options, including emerging therapies, for Cushing’s and acromegaly
2. Discuss surgical outcomes and risk management for pituitary and skull base tumors
3. Describe recent advances in pituitary neuropathology and neuroimaging
4. Critically appraise the role of radiation therapy in the management of pituitary tumors
5. Debate treatment decisions supporting the use and timing of new therapies for aggressive and malignant pituitary tumors
6. Provide a forum for pituitary patients to discuss treatment options and new therapies with providers and other patients

*Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities. For more information, please visit our Help page.

By registering for the live virtual course, you will be able to view presentations, hear live audio, and interact online. All sessions presented live on December 5, 2020, will be recorded and made available to attendees for viewing after the course. CME and ABIM MOC credit will be offered for this course and a certificate will be available after a post-course evaluation is complete. This live virtual course will be delivered using Zoom. We encourage all attendees to download the Zoom app prior to the start of the course (zoom.us/download). Additional access details will be emailed to all attendees before the course.   

Registration Discounts/Promotions 

• MSK is pleased to invite patients and caregivers to attend this course on a complimentary basis. If you are a patient or caregiver interested in attending, please email [email protected] to register (registration is required in order to attend).
• MSK CME offers a discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact [email protected] for more information.
• MSK employee registration is complimentary. However, you must complete course registration in order to attend this course. If you are registered for this course and are unable to attend, please email [email protected].
• If you would like to register the day of the meeting, 12/5/20, please email, [email protected]. 

Please note that after your payment has been processed, no further promotional discount adjustments will be made to your registration.

Cancellation Policy

If you cancel your participation in this course, your registration fee, less a $25 administrative fee, will be refunded when email notification is received by the MSK Office of Continuing Medical Education (MSK CME) at least 7 days prior to the first day of the course ([email protected]).

Cancellations or no-shows after this date are not eligible for a refund. MSK CME reserves the right to cancel or postpone any course due to unforeseen circumstances. In the unlikely event we must cancel or postpone this course, we will refund the registration fee in full, but are not responsible for any related costs, charges, or expenses to participants, including fees incurred by airline/travel/lodging agencies. At any time, you may substitute another registrant in your place after contacting MSK CME with the relevant information.

If it has been more than 120 days since you paid for a course, or submitted a check for payment, a W9 form will need to be completed for us to refund your registration. You will not be taxed on your refund.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ANCC CNE Statement

 Memorial Sloan Kettering Cancer Center–Nursing Professional Development /Continuing Education is accredited with distinction as a provider of nursing continuing professional development (NCPD) by the American Nurses Credentialing Center’s Commission on Accreditation.
 
6.5 NCPD credits will be awarded to participants who attend the program in its entirety and complete a program evaluation. Partial credit not awarded.

Endorsed by:
Pituitary Network Association (PNA)
Cushing’s Support & Research Foundation (CSRF)
Acromegaly Community

MSK Course Directors

Viviane Tabar, MD
Director, Pituitary & Skull Base Tumor Center
Theresa Feng Chair in Neurosurgical Oncology
Chair, Department of Neurosurgery

Eliza B. Geer, MD
Medical Director, Pituitary & Skull Base Tumor Center
Associate Attending
Endocrinology Service
Department of Medicine

Marc A. Cohen, MD, MPH
Surgical Director, Pituitary & Skull Base Tumor Center
Associate Attending
Head and Neck Service
Department of Surgery

Invited Keynote Speaker

Lynnette Nieman, MD
Senior Investigator
Chief, Endocrinology Consultation Service
National Institutes of Health
Bethesda, MD

Invited Course Faculty 

Anthony P Heaney, MD, PhD
Professor of Medicine
Burnett Family Endowed Chair in Neuroendocrinology
Co-Chief, Division of Endocrinology
UCLA Medical Center
Los Angeles, CA

MSK Course Faculty 

Patient Track Moderators

Jessica Diller Kovler, AM, MA, PhD
Board Member
Pituitary Network Association

Leslie Edwin
President 
Cushing’s Support & Research Foundation 

Jackie Hubbard 
Executive Director
Pituitary Network Association

Jill Sisco
President
Acromegaly Community

Invited Patient Speakers 

Lori Pulver, PT, MSPT, COS-C 
Scot “Froggy” Langley
Nicole "Nina" Foster

Faculty Disclosures (All Faculty)

Saturday, December 5, 2020

Memorial Sloan Kettering gratefully acknowledges the following organizations for providing educational grants and financial support for this live activity:

Chiasma
Corcept Therapeutics
Recordati Rare Diseases, Inc.
Strongbridge Biopharma plc